A recent study conducted by researchers from the Mayo Clinic and Germany's Dresden Technical University Medical Center has revealed that denosumab, odanacatib and antibodies against the bone formation inhibiting proteins like sclerostin and dickkopf-1 have shown persistent result in slowing the bone loss and boosting bone formation.

The website of the Genetic Engineering and Biotechnology News has displayed that a monoclonal antibody, denosumab, has succeeded to credit approval from the U. S. Food and Drug Administration in the year 2010, and declared safe for use among the postmenopausal women with osteoporosis.

Further, the medicine has a significant impact on the RANK ligand, a kind of protein that signals specialized cells, osteoclasts, that breaks down the bone tissue. In association with the RANK ligand, the badly blocked and weak bones tend to increase their mass naturally without the devastating interference of osteoclastic overactivity.

Odanacatib has almost similar functionality besides the fact that instead of preventing molecular messengers from initiating the breakdown of bone minerals, it slows down one of the enzymes.

According to the National Osteoporosis Foundation, approximately 22 million people, particularly in the US, suffer from the osteoporosis or the low bone mass.